Search results
Results from the WOW.Com Content Network
RNT contrasts with sealed-source therapy (brachytherapy) where the radionuclide remains in a capsule or metal wire during treatment and needs to be physically placed precisely at the treatment position. [4] When the radionuclides are ligands (such as with Lutathera and Pluvicto), the technique is also known as radioligand therapy. [5]
Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell. [1] It is a form of unsealed source radiotherapy.In cancer therapy, an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to the tumor cells.
Radiation therapy (RT) is in itself painless, but has iatrogenic side effect risks. Many low-dose palliative treatments (for example, radiation therapy to bony metastases) cause minimal or no side effects, although short-term pain flare-up can be experienced in the days following treatment due to oedema compressing nerves in the treated area ...
Body sites in which brachytherapy can be used to treat cancer. Brachytherapy is commonly used to treat cancers of the cervix, prostate, breast, and skin. [1]Brachytherapy can also be used in the treatment of tumours of the brain, eye, head and neck region (lip, floor of mouth, tongue, nasopharynx and oropharynx), [10] respiratory tract (trachea and bronchi), digestive tract (oesophagus, gall ...
Radionuclide therapy can be used to treat conditions such as hyperthyroidism, thyroid cancer, skin cancer and blood disorders. In nuclear medicine therapy, the radiation treatment dose is administered internally (e.g. intravenous or oral routes) or externally direct above the area to treat in form of a compound (e.g. in case of skin cancer).
Pages for logged out editors learn more. Contributions; Talk; Unsealed source radiotherapy
Targeted alpha-particle therapy (or TAT) is an in-development method of targeted radionuclide therapy of various cancers. It employs radioactive substances which undergo alpha decay to treat diseased tissue at close proximity. [1] It has the potential to provide highly targeted treatment, especially to microscopic tumour cells.
Tositumomab is a murine monoclonal antibody which targets the CD20 antigen produced in mammalian cell. [1] It was combined with iodine-131 to produce a radiopharmaceutical for unsealed source radiotherapy, Iodine-131 Tositumomab (branded as Bexxar), for the treatment of non-Hodgkins lymphoma. [1]